The DARPin Difference

Transcription

1 The DARPin Difference Offering Patients a New Dimension of Protein Therapeutics Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) March Molecular Partners AG - 1

2 Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like potential, believe, assume, expect, forecast, project, may, could, might, will or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit Molecular Partners AG - 2

3 Molecular Partners: Who We Are $ Teamwork Swiss biotech 100 team members Discovery to phase 2 (POC) Science & patients first DARPin Therapies High patient value DARPin Difference Abicipar in phase 3 (ophtha) MP0250 in phase 2 (onco) MP0274 in phase 1 (onco) Broad preclin. I/O portfolio Long-term Partnerships Alliance with Allergan Swiss listing (MOLN) Cash CHF180mn* Financed well beyond key value inflection points DARPin Platform DARPin Difference: unlock novel modes of action Proof of Platform in the eye and systemically Fast and cost effective drug discovery engine *As of Q4/16. I/O, immuno-oncology Molecular Partners AG - 3

4 DARPin Difference DARPin Differentiation I/O DARPin proteins: Tumorrestricted activity, MP0274: Molecular Handcuff forcing HER2+ cancer cells into apoptosis MP0250: Blocking two escape pathways Abicipar: Long-acting DARPin protein Patient Benefit Opening a new therapeutic window for combinations For patient not profiting from SOC antibodies with ADCC Restore activity of SOC when cancer becomes resistant Less frequent ocular injections Status Preclin Ph1 Ph2 Ph3 Our strategy: Differentiated DARPin products with high patient value 2017 Molecular Partners AG - 4

5 DARPin Proteins: A Different Class of Therapeutics DARPin is a registered trademark owned by Molecular Partners AG Abicipar: Mono-DARPin MP0250: Multi-DARPin (4x) Mono-DARPin : selected to bind a given target with high affinity & specificity (large libraries) Multi-DARPin : linked mono-darpin ( six) & directly used for functional screening Ideal properties: mono- & multi-darpin are soluble, stable with a high-yield production Natural principle: repeat proteins were evolved as binders in multifunctional contexts Proof of Platform: Low immunogenicity* and long half-life in bloodstream and eye *MP0250 phase 1 study results show sustained exposure indicating absence of clearing antibodies; Systemic half-life of ~12 d (MP0250 phase 1), 14 d in the eye (abicipar) Molecular Partners AG - 5

6 Pathway to the DARPin Difference DARPin Difference Identify unique Product Candidate Patient Need Define Target(s) Mono-DARPin Library (>10 12 ) Screen for desired phenotype Apoptosis Activation via clustering Build multi-darpin library >10,000 multi- DARPin combinations Select highly diverse of mono-darpin proteins to various epitopes 2017 Molecular Partners AG - 6

7 Long-term Partnerships: Investors & Pharma Balance capital markets and pharma partnering as sources of capital > CHF 360mn collected so far from investors and partners Remain in strong cash position to fund pipeline progress $ Strategic alliance with Allergan in ophthalmology Initiated with Abicipar in 2011 Up to $360mn open milestone potential & low double-digit to mid-teen tiered royalties Expanded into broad discovery alliance in 2012 Potential $1.4bn future milestone & tiered royalties to the mid-teen range Partnering strategy: leverage the potential of the DARPin platform Platform and pipeline are deeper than what Molecular Partners can access alone Partnering opportunities open on multiple levels 2017 Molecular Partners AG - 7

8 Ophthalmology Imm. I/O Oncology Balanced Portfolio Discovery Preclinical Phase 1 Phase 2 Phase 3 MP0250 in multiple myeloma MP0250 in a solid tumor indication Ph2 in preparation MP0274: HER2 multi-darpin PD-1/VEGF multi-darpin Tumor-restricted agonist Several discovery programs MP0230: IL-13/IL-17 multi-darpin Abicipar in wet AMD Abicipar in DME VEGF/PDGF multi-darpin Several discovery programs partnership AMD, age-related macular degeneration; DME, diabetic macular edema Molecular Partners AG - 8

9 Oncology 2017 Molecular Partners AG - 9

10 The DARPin Difference in Oncology TUMOR PATHWAYS Current Challenges Unlimited growth Sustained angiogenesis Tissue invasion & metastasis Evades body s immune defense Current Strategies Attack from several angles (combo treatment) Activate immune system (immuno-oncology) TUMOR MICROENVIRONMENT DARPin Difference DARPin candidates targeting multiple pathways Tumor-localized multi-darpin candidates Novel modes of action (MoAs) 2017 Molecular Partners AG - 10

11 MP0250: An Ideal Combination (anti-vegf & HGF) MP0250 MP0250 First bi-specific biologic targeting VEGF and HGF Molecular Partners holds all rights anti-hsa DARPin Development Stage Differentiation & Potential Benefit Phase 1: solid tumor study Demonstrated good tolerability and exposure, encouraging efficacy Phase 2: multiple myeloma study Regulatory submission Q4/2016 Initial safety data expected 2017 Initial efficacy data expected 2018 Additional Phase 2 for solid tumor indication planned for 2017 Potentially ideal for patients with likely VEGF- and/or HGF-mediated escape from previous treatment Can be combined with standard therapy anti-vegf DARPin anti-hsa DARPin anti-hgf DARPin 2017 Molecular Partners AG - 11

12 MP0250 Blocks Tumor Escape MP0250 Untreated SOC Alone SOC + MP0250 VEGF VEGF VEGF TUMOR HGF HGF HGF PATHWAYS MP Molecular Partners AG - 12

13 MP0250 Attacks Tumor on Several Levels MP0250 TUMOR PATHWAYS VEGF MP0250 potential VEGF HGF Directly inhibits tumor growth & survival HGF VEGF HGF HGF VEGF HGF Induces unfavorable tumor microenvironment VEGF T-cell HGF HGF VEGF HGF TUMOR ESCAPE MECHANISM Inhibits tumor escape from treatment (& metastasis) 2017 Molecular Partners AG - 13

14 Tumor Volume (mm 3 ) Relative Tumor Volume (mm 3 ) MP0250: Combination With Chemotherapy and Biologics Across Diverse Cancers MP MP PD-1 mab Colorectal Cancer* 800 MP Paclitaxel Gastric Cancer** Vehicle 600 Vehicle Anti-PD Treatment (Days) MP0250 MP Anti-PD Paclitaxel MP0250 MP Paclitaxel Treatment (Days) MP0250 has also been tested in preclinical models of renal, liver and lung cancer *MC38 syngeneic mouse model; **Patient-derived xenograft: GXA Molecular Partners AG - 14

15 Dose Cohorts (mg/kg) & Patients MP0250: Good Tolerability and Signs of Efficacy in Phase 1 Solid Tumor Study MP0250 Tolerability MTD determined (8 mg/kg/q2w) Main AEs consistent with profound VEGF pathway inhibition Hypertension (66%), partially Grade 3 Proteinuria (29%), mainly Grade 1 or 2 Systemic data Half-life: 12 days No clearing or neutralizing ADA (0/24 patients) Efficacy Significant reductions in tumor volume in 2 patients with 1 confirmed PR Stable disease at 12 wk in 10 patients (42%) Treatment Duration of Individual Patients (N=24)* ** ** Weeks *Study ongoing. Data cut-off June 2016 (N=24 patients). ** Ongoing Molecular Partners AG - 15

16 Biological rationale* Internal Evaluation of MP0250 Potential MP0250 EGFR-mutated non-small cell lung cancer Nasopharyngeal Head & neck squamous-cell HCC Multiple myeloma Colorectal cancer Anal cancer Feasibility of internal clinical development* Bubble size indicates estimated relative market potential (incidences; source: Datamonitor). *Based on internal assessment on speed to market and complexity of development program. Potential of gastric cancer, renal cancer and other cancers under evaluation Molecular Partners AG - 16

17 p-cmet p-cmet Preclinical and Clinical Data Support MP SOC for Multiple Myeloma MP0250 Preclinical Rationale Vehicle Tumor Growth H929 Xenograft MP Bortezomib HGF Rationale Clinical Rationale HGF Receptor Activation 1 Newly diagnosed On partial remission 28% 2% Muscle invasion Resistant 40% SOC Relapsed 92% 89% Bone morphology cmet 3% 7% cmet 1. Moschetta M, et al. Clin Cancer Res 2013;19: ; 2. White D, et al. Cancer 2013;119: Molecular Partners AG - 17 VEGF Rationale A small MM study of bevacizumab (Avastin ) + bortezomib (Velcade ) demonstrated benefit over bortezomib alone 2

18 MP0274: Killing HER2+ Cells With New MoA MP0274 MP0274 Development Stage Multi-DARPin protein binding two distinct HER2 epitopes Indications: patients with HER2-addicted tumors Molecular Partners holds all rights First regulatory submission in Q4/2016 Handcuff as Master Switch HER2 Bi-paratopic DARPin Differentiation & Potential Benefit Induces apoptosis (cell death) in HER2+ tumor cells without ADCC New MoA may help patients who do not adequately respond to current therapies HER2 Pertuzumab (Perjeta ) Trastuzumab (Herceptin ) ADCC, antibody dependent cell-mediated cytotoxicity Molecular Partners AG - 18

19 Direct Induction of Tumor Cell Death Is Unique to MP0274 MP0274 MP0274 «Open» HER2 + MP0274 «locked» Apoptosis HER2 HER3 Locks (handcuffs) HER2 into inactive conformation, inhibits dimerization Effector-cell independent tumor cell death Natural Killer Cell HER2 signals tumor cell survival & proliferation ADCC Herceptin & Perjeta Effector-cell mediated tumor cell death 2017 Molecular Partners AG - 19

20 Tumor Volume (mm 3 ) Apoptotic cells (%) MP0274 Kills by Apoptosis, Not ADCC MP Tumor Volume PDX: Breast Cancer HER Tumor Cell Apoptosis BT474 MP Vehicle Herceptin MP0274 Herceptin / Perjeta Herceptin / Perjeta Days After Treatment Initiation [nm] MP0274 is as efficacious as SOC without the help of the immune system New MoA may help patients who do not adequately respond to current therapies 2017 Molecular Partners AG - 20

21 Immuno-Oncology 2017 Molecular Partners AG - 21

22 Molecular Partners Strategy for T-Cells KILL T-Cell Engagers T-cell ACTIVATE Costimulatory Targets BLOCK Checkpoint Targets Tumor Cell 2017 Molecular Partners AG - 22

23 Enhanced Efficacy of Established I/O Concept Multi-DARPin Protein PD-1/VEGF PD-1/VEGF PD-1/VEGF Multi-DARPin Inhibits PD-1 and VEGF Rationale: ideal backbone in all indications where PD-1/VEGF will become gold standard anti-hsa DARPin Differentiation & Potential Benefit Molecular Partners holds all rights Normalization of tumor vasculature to enhance immune cell infiltration and PD-1 efficacy Opportunity for More patients to respond to anti-pd-1 therapy Use across more indications compared with PD-1 monotherapy anti-vegf DARPin anti-pd-1 DARPin 2017 Molecular Partners AG - 23

24 Combining Anti-PD-1 and anti-vegf DARPins Leads to Strong Tumor Growth Inhibition PD-1/VEGF Median Tumor Volume (MC38 model) Individual Tumor Volumes, Day Vehicle p= Anti-VEGF Anti-PD mm Anti-PD-1 + anti-vegf Treatment (Days) 0 Vehicle Anti-VEGF Anti-PD-1 Anti-PD-1 + Anti-VEGF Syngeneic MC38 mouse tumor model assessing surrogate anti-pd-1 DARPin and cross-reactive anti-vegf DARPin 2017 Molecular Partners AG - 24

25 Unleashing Potential of Agonists in I/O Agonistic mab: IN CIRCULATION (SYSTEMIC) IN THE TUMOR Activated Activated T-cell agonist target T-cell Cell T-cell Tumor Cell Tumor-restricted DARPin Agonists IN CIRCULATION (SYSTEMIC) IN THE TUMOR Tumor Stroma anti-hsa DARPin Agonist DARPin T-cell Activated Local cluster DARPin Cell 2017 Molecular Partners AG - 25 Tumor Cell

26 Combinations in I/O drug combination Systemic side effects potentially limiting PD-1 antibody VEGF antibody Systemic agonistic antibody anti-vegf DARPin anti-pd-1 DARPin PD-1/VEGF multi-darpin + Local cluster DARPin Agonist DARPin Tumor-restricted agonist 2-drug combination Open therapeutic window with reduced side effects Combination of choice 2017 Molecular Partners AG - 26

27 Ophthalmology 2017 Molecular Partners AG - 27

28 Abicipar: Most Advanced DARPin Therapy Abicipar Abicipar Long-acting pegylated mono-darpin protein blocking VEGF Indications: Wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) Global license agreement with Allergan anti-vegf DARPin Development Stage Phase 3 2 registration-enabling studies in wet AMD initiated July 2015 Clinical trial in DME planned by Allergan for H Phase 2 DME data presented at AAO 2016 Differentiation & Potential Benefit Less frequent ocular injections compared with standard of care All development costs borne by Allergan 2017 Molecular Partners AG - 28

29 CAGR: 18% Retinal Diseases: Unmet Medical Needs Remain Wet AMD and DME are leading causes of blindness in western world Large and rapidly growing group driven by again population Current standard of care is Lucentis and Eylea Significant unmet medical need for less frequent injections and doctor office visits Global Wet AMD and DME Market Size (USDbn) 1 * Ranibizumab (Lucentis ) Aflibercept (Eylea ) Other Reported by EvaluatePharma, a service of Evaluate Ltd. (UK), Accessed 27 Apr *Avastin is used off label Molecular Partners AG - 29

30 BCVA (letters ± SE) Phase 2 Data Suggest Quarterly Dosing for Wet AMD Abicipar Change of Best-Corrected Visual Acuity (BCVA)* 12 Abicipar 2.0 mg 10 Abicipar 1.0 mg Lucentis 0.5 mg Safety Data Vision Gain (letters) Safety (n/n) Wk 16 Wk 20 Aes** / / / Week The abicipar formulation has been further optimized for safety for use in phase 3 Dosing Allergan, 12 August *Study not powered to reach statistical significance; **Ocular inflammation. AE, adverse event Molecular Partners AG - 30

31 CEDAR and SEQUOIA: Abicipar Registration Studies in Wet AMD Abicipar Loading Doses Primary Endpoint Extension Abicipar 2 mg q12w Abicipar 2 mg q8w Lucentis 0.5 mg q4w Week parallel, randomized, double-blind phase 3 studies Expected global enrollment: 900 patients/study Estimated study completion: Aug 2018 Drug Safety Monitoring Committee (DSMC): no changes recommended Q4/16 Next milestone: full study enrollment expected Aug Molecular Partners AG - 31

32 Mean Change in BCVA (letters ± SE) Phase 2 Data: Long Duration of Action in DME Abicipar Loading Doses Primary Endpoint Vision gain (letters) Safety Week Wk 28 AEs (n/n) Abicipar 2 mg q12w Abicipar 2 mg q8w Abicipar 1 mg q8w Lucentis 0.5 mg q4w 7.2 4/ / / / The abicipar formulation has been further optimized for safety for use in Phase Lucentis 0.5 mg q4w Abicipar 2 mg q12w Week 2017 Molecular Partners AG - 32

33 Allergan View on Abicipar at JPM Molecular Partners AG - 33

34 DARPin Strategy in Ophthalmology Partnership with Allergan Value Status Discovery Alliance: Multi-DARPin concepts in the eye Next generation products Preclin Abicipar in DME: less frequent ocular injections Start of phase 3 as early derisking for safety read-out Ph2 Abicipar in wet AMD: less frequent ocular injections Low biology risk with meaningful differentiation Ph3 Extract from ALLERGAN Presentation; JP Morgan Conference; January 9, 2017 by Brent Saunders; Chairman and CEO 2017 Molecular Partners AG - 34

35 Immunology 2017 Molecular Partners AG - 35

36 MP0230 Fact Sheet MP0230 MP0230 Targets unique combination of IL-13 & IL-17 (Th2 & Th17) Rights regained from Janssen after their decision to exit pulmonary indications anti-hsa DARPin anti-il-13 DARPin anti-il-17 DARPin Rationale & Development Stage Outlook anti-hsa DARPin Various inflammatory diseases are driven by Th2- and/or Th17-mediated pathology (asthma, COPD, atopic dermatitis others) Pulmonary model shows superiority of dual vs mono cytokine neutralization Long systemic half-life in monkeys, suggesting up to monthly dosing MP0230 is ready for preclinical development with 18 months to IND Partnering or internal development under evaluation 2017 Molecular Partners AG - 36

37 Cells/mL Cells/mL Rn (cmh 2 O/mL/sec) MP0230: Rationale and Predicted Patient Benefit MP0230 Biological Rationale Potential Patient Benefit Th17 Naïve T-Cell Th2 3 2 Th2/Th17 + IgG αil-17a αil-13 * * IL-17 IL-13 IL-4 1 αil-13/αil-17a Hypersensitivity Airway Neutrophilis Inflammation Eosinophilis 0 BL Methacholine (mg/ml) *p <0.05 vs αil-13 or αil-13/αil-17a p <0.05 vs αil-13/αil-17a 0 MP0230 prevents both neutrophil- & eosinophilassociated pathology 0 Broader clinical response expected Single pathway inhibition may cause disease escape via comp. pathways IL-13 inhibition can promote IL-17 production 2017 Molecular Partners AG - 37

38 Summary 2017 Molecular Partners AG - 38

39 Outlook 2017 & Beyond MP0250: Multiple Myeloma MP0250: additional solid tumor ind. MP0274: Her2 multi-darpin PD-1/VEGF multi-darpin Tumor-restricted agonist Several discovery programs Initial safety data Ph2* Submission for Ph2 First dosing in Ph1 Preclinical data Initial efficacy data Ph2 Initial data Ph2 Initial data Ph1 Abicipar**: wet AMD Abicipar**: DME Full enrollment of Ph3 Start of Ph3 1-year efficacy data Ph3 Cash CHF 180mn (Q4/16) Financed well beyond key value inflection points *Definition of the safe dose of MP0250 in combination with Velcade allowing transition to the efficacy part of the study **Abicipar under development and control of Allergan. All costs borne by Allergan Molecular Partners AG - 39

40 Conclusions Balanced & differentiated clinical DARPin portfolio: Abicipar phase 3 in wet AMD and phase 2 concluded in DME MP0250 phase 2 submitted in MM and solid tumor phase 2 in prep. MP0274 phase 1 submitted in HER2+ cancers Broad DARPin portfolio in immuno-oncology $ Financed well beyond key value inflection points Full pipeline allows exploration of collaboration opportunities Strong and experienced team Culture of teamwork and «science and patients first» With proof of platform, we now focus on making the DARPin Difference real for patients 2017 Molecular Partners AG - 40

41 Appendix 2017 Molecular Partners AG - 41

42 Shareholder Structure Shareholder structure as of Dec 31, 2016 Highlights Listed on SIX Swiss Exchange (SIX: MOLN) 36% 22% 42% Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech 20,724,345 shares outstanding 1 CHF 514 million market cap. as of December 31, 2016 No lock-up restrictions in place Formal free float as per SIX definition: 66% Pre-IPO investors (5 VC's) Management, Board, Founders Others 1 Share capital increase will be registered in the Commercial Register in the course of Q Molecular Partners AG - 42

43 Strong Management Team Dr. Patrick Amstutz, acting CEO Co-founder, former CBO & COO PhD in Molecular Biology from UZH Dr. Andreas Harstrick, CMO, MD 28 years of experience in oncology Senior executive roles at Merck-Serono, Imclone, Eli Lilly Dr. Michael Stumpp, CSO Co-founder PhD and Postdoc from UZH; research in Tokyo, London Andreas Emmenegger, CFO Previously with Roche and GlycArt Former CFO of two listed companies 2017 Molecular Partners AG - 43

44 Experienced and Independent Board of Directors Jörn Aldag (Non-executive Chairman) CEO, Hookipa Biotech AG; Former CEO, uniqure and Evotec Steve Holtzman (Non-executive director) President and CEO, Decibel Therapeutics; Former EVP, Biogen Christian Zahnd (Founder, non-executive director) Former CEO and Co-founder, Molecular Partners Göran Ando (Non-executive director) Chairman, Novo Nordisk; former CSO, Pharmacia Bill Lee (Non-executive director) EVP Research, Gilead Petri Vainio (Non-executive director) Essex Woodlands Ventures Jeffrey H. Buchalter (Non-executive director) Former CEO Enzon and Ilex Oncology; senior roles at Pharmacia, Wyeth, Schering-Plough Andreas Plückthun (Founder, non-executive director) Professor, UZH; Co-founder, Morphosys 2017 Molecular Partners AG - 44

45 Financial Summary (CHF million; as per IFRS) FY 2016 FY 2015 change Revenues (6.1) Total expenses 1 (42.5) (31.3) (11.2) Operating result EBIT (19.5) (2.2) (17.3) Net financial result (1.2) Net result (18.6) (0.1) (18.5) Net cash from (used in) operations (35.4) 26.5 (61.9) Cash balance (35.2) 1 Thereof non-cash costs of CHF 4.7m in FY2016 and CHF 5.3m in FY Including CHF 20.0 million short-term time deposits 3 Including CHF 30.5 million short-term time deposits 2017 Molecular Partners AG - 45

46 Financial Guidance for Full Year 2017 Total expenses of ca. CHF million, of which around CHF 6 million non-cash effective costs Capital expenditures of ca. CHF 2 million come on top No guidance on net cash flow; timelines and potential milestones payments with partnerships not disclosed Guidance subject to progress and changes of pipeline 1 At constant exchange rates 2017 Molecular Partners AG - 46

47 IR Agenda Date Event March 31, 2017 Publication of Annual Report 2016 May 4, 2017 Q Management Statement May 11, 2017 Annual General Meeting for business year 2016 August 30, 2017 Publication of Half-year Results 2017 October 26, 2017 Q Management Statement 2017 Molecular Partners AG - 47

48 Molecular Partners AG Wagistrasse Zürich-Schlieren Switzerland T Molecular Partners AG - 48